Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2000

View Archived Issues

FDA okays Discovery's phase II trial with Surfaxin

Initiation of phase II CF trial with tgAAV-CF announced

Company Profile: Nobex

Reverse Na+/Ca2+ exchange inhibitor KB-R7943 studied in arrhythmia, reperfusion

New Tamiflu indication for prevention of influenza approved by FDA

Medarex and Epigen create antibody collaboration

Direct factor Xa inhibitor FXV-673 shows good results versus heparin

United Therapeutics and Antigen sign distribution agreement for UT-15

XTL hepatitis treatments make steady development progress

Australian company develops recombinant cytokine analogue with significant potential in cancer

MUP-98176: a new hypoxia-selective cytotoxic mustard prodrug

S-18886 improves endothelial function in CAD patients

Cytotoxic hydrazones with novel mechanism of action presented at recent cancer meeting

Biological profile of KF-58333, a new hsp90 antagonist derived from radicicol

CB1 cannabinoid receptor activation involved in cirrhosis-associated hypotension

Dose-dependent decreases in serum uric acid levels demonstrated for TMX-67 in early clinical trial

Company Profile: York Medical

Antidiabetic imidazoles in the Sankyo pipeline

Krenitsky presents pyrimidine-based neurotrophic compounds

Synthesis and use of new integrin antagonists in the therapy of asthma

Long-awaited HBV therapy launched in Japan

PGE1 derivatives from Taisho and use in cardiovascular disorders

New anti-HIV agents synthesized in Korea show high therapeutic index

R&D at Lilly leads to discovery of new series of 5-HT reuptake inhibitors

Novel antibacterial agents described in recent patent by British Biotech

FDA approves Boehringer Ingelheim's Micardis HCT

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...